Medicare GLP-1 Coverage 2026: The $50 Copay Bridge Program Explained
Starting July 1, 2026, Medicare will cover GLP-1 weight loss medications for the first time ever. Here is what seniors need to know about the new Bridge Program, which drugs are included, and how to qualify.
For years, Medicare beneficiaries have watched GLP-1 medications transform weight loss for millions of Americans — while remaining locked out due to a federal prohibition on coverage for obesity drugs. That changes on July 1, 2026. The Centers for Medicare & Medicaid Services (CMS) has announced the Medicare GLP-1 Bridge Program, which will cap monthly copays at $50 for eligible seniors taking FDA-approved GLP-1 medications for weight management.
The Short Answer
Starting July 1, 2026, Medicare Part D will cover FDA-approved GLP-1 weight loss medications (Wegovy, Zepbound, and the newly approved Foundayo) with copays capped at $50 per month for eligible beneficiaries. The program is called the Medicare Bridge Program and requires enrollment. It does not cover compounded or generic versions — only brand-name FDA-approved drugs.
Why This Is a Historic Shift
Since 2003, Medicare has been prohibited by law from covering medications used solely for weight loss. The statutory exclusion meant that even as GLP-1 drugs like Wegovy and Mounjaro demonstrated remarkable efficacy — and even as the FDA approved them specifically for chronic weight management — Medicare beneficiaries had to pay out of pocket or go without.
The Bridge Program is CMS's first major step toward treating obesity as the chronic disease the medical community now recognizes it to be. It represents a direct acknowledgment that GLP-1 medications are not cosmetic treatments but essential therapeutics for metabolic health, cardiovascular risk reduction, and quality of life.
The Numbers Behind the Need
of adults 60+ live with obesity
average monthly retail cost of Wegovy before coverage
new maximum monthly copay under the Bridge Program
Which Medications Are Covered?
The Bridge Program covers FDA-approved GLP-1 and dual-agonist medications prescribed for chronic weight management. Here is the current list as of May 2026:
| Medication | Active Ingredient | Type | Form | Est. Monthly Cost |
|---|---|---|---|---|
| Wegovy | Semaglutide | GLP-1 agonist | Weekly injection | $50 copay |
| Wegovy (oral) | Semaglutide 25mg | GLP-1 agonist | Daily pill | $50 copay |
| Zepbound | Tirzepatide | Dual GIP/GLP-1 | Weekly injection | $50 copay |
| Foundayo | Orforglipron | Oral GLP-1 | Daily pill | $50 copay |
| Mounjaro | Tirzepatide | Dual GIP/GLP-1 | Weekly injection | Covered for diabetes; weight use TBD |
Important: The Bridge Program does NOT cover compounded semaglutide or tirzepatide, nor does it cover unapproved generic copies from compounding pharmacies. Only FDA-approved brand-name medications dispensed through licensed retail or specialty pharmacies are eligible. If you are currently using compounded products, you will need to transition to a covered brand-name drug to receive the $50 copay.
Who Qualifies for the Bridge Program?
Eligibility is more restrictive than commercial insurance coverage. CMS has designed the program to target beneficiaries with the highest clinical need and strongest evidence base for benefit.
Medicare Part D Enrollee
You must be actively enrolled in a Medicare Part D prescription drug plan or a Medicare Advantage plan that includes prescription drug coverage (MA-PD).
BMI Criteria
BMI of 30 or higher (obesity) OR BMI of 27 or higher (overweight) with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea.
Clinical Evaluation
A documented in-person or telehealth evaluation by a licensed prescriber within the 12 months prior to enrollment. The evaluation must include a weight history, comorbidity assessment, and discussion of treatment risks and benefits.
Prior Documentation
Documentation of prior weight loss attempts through lifestyle modification (diet and exercise) for at least 6 months, or documentation of why such attempts were not feasible or effective. This requirement may be waived for patients with BMI over 40 or significant obesity-related complications.
Exclusion Criteria
Patients with personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), history of pancreatitis, severe gastroparesis, or current pregnancy are excluded from coverage under the Bridge Program.
How to Enroll: Step-by-Step
Enrollment is not automatic. You must opt in and complete a structured process before your first $50-copay prescription fill. Here is what the enrollment process looks like:
Confirm Your Part D or MA-PD Coverage
Contact your plan directly or check Medicare.gov to confirm your plan is participating in the Bridge Program. Most national plans (UnitedHealthcare, Humana, Aetna, Blue Cross Blue Shield affiliates) have confirmed participation, but some smaller regional plans may lag.
Schedule a Clinical Evaluation
If you have not had a weight management visit with a licensed prescriber in the past 12 months, schedule one. This can be done via telehealth or in-person. Your prescriber will document your BMI, comorbidities, and weight history.
Complete the Bridge Program Enrollment Form
Your prescriber will submit a Bridge Program enrollment form to CMS through your Part D plan. This form includes your BMI, qualifying comorbidities, prior weight management attempts, and attestation that you have been counseled on risks and benefits.
Wait for CMS Approval
CMS has committed to a 14-day turnaround for enrollment decisions. During this period, you may be responsible for the full cost of medication if you choose to fill a prescription. Most plans recommend waiting for approval before starting.
Fill Your Prescription at a Participating Pharmacy
Once approved, your Part D plan will issue a Bridge Program authorization. You can fill your prescription at any in-network retail or specialty pharmacy. The copay will be capped at $50 at the point of sale. Mail-order options are available for most plans.
Annual Re-Authorization
Bridge Program enrollment lasts 12 months. To continue beyond the first year, you must complete an annual re-evaluation with your prescriber and re-submit the enrollment form. This ensures ongoing clinical appropriateness and tracks outcomes.
What Does This Actually Cost?
The $50 monthly copay cap is the headline number, but understanding your total cost requires looking at the full picture — including plan premiums, deductibles, and any additional fees.
What You Will Pay
- $50/month maximum copay for covered GLP-1 medications at in-network pharmacies
- $0 for Bridge Program enrollment itself
- $0 for annual re-authorization processing
- Standard Part D plan premiums continue to apply (varies by plan)
What You Might Still Pay For
- Telehealth or office visit copays for your prescriber evaluation (typically $0-$40)
- Out-of-network pharmacy fills — you may pay the full cost plus difference
- Non-covered medications like compounded products or experimental drugs
- Plan deductible still applies if your plan has one before the $50 copay kicks in
Medicare Advantage vs. Original Medicare: What Is Different?
The Bridge Program applies to both Medicare Advantage (Part C) with prescription drug coverage and standalone Part D plans, but there are some practical differences in how enrollment works.
| Feature | Original Medicare + Part D | Medicare Advantage (MA-PD) |
|---|---|---|
| Enrollment | Direct through CMS.gov or your Part D plan | Through your MA plan's member portal |
| Prior Authorization | Standard 14-day CMS review | May have additional plan-specific requirements |
| Pharmacy Network | Broad — any in-network pharmacy | Often narrower — may require specialty pharmacy |
| Mail Order | Optional through plan's mail service | Often required or strongly incentivized |
| Copay Cap | $50/month guaranteed | $50/month guaranteed, but may have step therapy rules |
What If You Do Not Qualify or Need an Alternative?
Not everyone will qualify for the Bridge Program, and not everyone wants brand-name medications. If you fall into any of these categories, compounded GLP-1 medications from a licensed telehealth pharmacy remain a valid and accessible option:
You are on a Medicare plan that has not yet opted into the Bridge Program
Your BMI or comorbidity profile does not meet the strict CMS criteria
You prefer an oral or alternative formulation not covered by the Bridge Program
You are under 65 and on Medicare disability (eligibility criteria may differ — check with your plan)
You need to start treatment before July 1, 2026 or before your enrollment is approved
Need an Alternative Now?
Compounded semaglutide and tirzepatide from Halo-RX are available today at $199/month and $299/month — no insurance required, no enrollment waiting period, and no prior authorization needed.
Licensed pharmacist oversight. Discreet home delivery. Same active ingredients as Wegovy and Zepbound.
Frequently Asked Questions
Does Medicare cover Ozempic under the Bridge Program?
Ozempic is FDA-approved for type 2 diabetes, not chronic weight management. The Bridge Program specifically covers medications approved for weight loss: Wegovy, Zepbound, and Foundayo. If you are taking Ozempic for diabetes, it may already be covered under standard Part D rules depending on your plan's formulary. If you are taking it off-label for weight loss, it will not be eligible under the Bridge Program.
When exactly does the Bridge Program start?
The program launches on July 1, 2026. Enrollment opens June 1, 2026, so you can begin the application process a month early. However, the $50 copay cap only applies to prescriptions filled on or after July 1. If you fill before that date, you will pay your plan's standard cost-sharing amount, which could be hundreds or thousands of dollars depending on your plan's tier placement for GLP-1 drugs.
Can I use the Bridge Program with a Medicare Supplement (Medigap) plan?
Medigap plans do not include prescription drug coverage. The Bridge Program requires active Part D or MA-PD enrollment. If you have Original Medicare plus a Medigap plan but no Part D plan, you will need to enroll in a Part D plan to access the Bridge Program. You can do this during the Annual Enrollment Period (October 15 - December 7) or during a Special Enrollment Period if you qualify.
Will the Bridge Program cover retatrutide when it is approved?
CMS has stated that the Bridge Program will be updated to include new FDA-approved GLP-1 and related incretin medications for weight management as they receive approval. Eli Lilly's retatrutide, the triple agonist currently in Phase 3 trials, is expected to be reviewed by the FDA in late 2026 or early 2027. If approved for weight management, it will likely be added to the covered list. The program is designed to be formulary-flexible rather than locked to today's specific drugs.
What happens if I switch Medicare plans during the year?
Bridge Program enrollment is tied to your specific Part D or MA-PD plan. If you switch plans during the year (for example, during the Annual Enrollment Period or a Special Enrollment Period), you will need to re-enroll in the Bridge Program under your new plan. Your prior authorization does not automatically transfer. Plan ahead if you are considering a switch — complete your new plan enrollment first, then submit a new Bridge Program application.
Is the Bridge Program permanent or temporary?
CMS has designated the Bridge Program as a 5-year pilot program running from July 1, 2026 through June 30, 2031. The program will collect data on outcomes, costs, and utilization to inform Congress on whether to make Medicare GLP-1 coverage permanent through legislation. During the pilot period, the $50 copay cap and covered drug list are guaranteed. After 2031, coverage will depend on congressional action and program evaluation data.
Do I need to lose weight on my own before enrolling?
The Bridge Program requires documentation of prior lifestyle modification attempts (diet and exercise) for at least 6 months, or a documented reason why such attempts were not feasible. This does not mean you need to achieve a specific amount of weight loss first — just that you have attempted structured lifestyle change. Your prescriber can document this based on your medical history. Patients with BMI over 40 or severe obesity-related complications may have this requirement waived.
What if my doctor prescribes a dose not covered by my plan?
Some Part D plans may have quantity limits or step therapy requirements (e.g., requiring trial of a lower-cost GLP-1 before covering a higher-cost one). The Bridge Program guarantees $50 copay coverage for all listed medications, but your plan may still apply utilization management rules. If your prescriber believes a specific dose or medication is clinically necessary, they can submit a formulary exception or prior authorization request. The Bridge Program does not override plan-specific quantity limits unless medically justified.
The Bottom Line
The Medicare GLP-1 Bridge Program is a watershed moment for older Americans living with obesity. For the first time, millions of Medicare beneficiaries will have affordable access to the most effective weight management medications ever developed. If you or a loved one is on Medicare and struggling with weight, the time to start preparing is now.
If you do not qualify for the Bridge Program, need to start treatment before July 2026, or simply prefer a compounded alternative, Halo-RX offers compounded semaglutide and tirzepatide at a fraction of retail brand-name pricing — with licensed pharmacist oversight and discreet home delivery.